These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 11349057)

  • 41. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation.
    Dobaño C; Widera G; Rabussay D; Doolan DL
    Vaccine; 2007 Sep; 25(36):6635-45. PubMed ID: 17669562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine.
    Chattopadhyay R; Conteh S; Li M; James ER; Epstein JE; Hoffman SL
    Vaccine; 2009 Jun; 27(27):3675-80. PubMed ID: 19071177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasmodium yoelii: the role of the individual epidermal growth factor-like domains of the merozoite surface protein-1 in protection from malaria.
    Calvo PA; Daly TM; Long CA
    Exp Parasitol; 1996 Jan; 82(1):54-64. PubMed ID: 8617331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice.
    Noland GS; Chowdhury DR; Urban JF; Zavala F; Kumar N
    Vaccine; 2010 Apr; 28(17):2917-23. PubMed ID: 20188676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and protective efficacy of three DNA vaccines encoding pre-erythrocytic- and erythrocytic-stage antigens of Plasmodium cynomolgi in rhesus monkeys.
    Bhardwaj D; Hora B; Singh N; Puri SK; Lalitha P; Rupa P; Chauhan VS
    FEMS Immunol Med Microbiol; 2002 Sep; 34(1):33-43. PubMed ID: 12208604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development.
    Inoue M; Tang J; Miyakoda M; Kaneko O; Yui K; Culleton R
    Int J Parasitol; 2012 Aug; 42(9):859-70. PubMed ID: 22846785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice.
    Sakai T; Hisaeda H; Nakano Y; Zhang M; Takashima M; Ishii K; Maekawa Y; Matsumoto S; Nitta Y; Miyazaki Ji; Yamamoto S; Himeno K
    Vaccine; 2003 Mar; 21(13-14):1432-44. PubMed ID: 12615440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
    Dobaño C; Doolan DL
    Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
    Rainczuk A; Smooker PM; Kedzierski L; Black CG; Coppel RL; Spithill TW
    Vaccine; 2003 Jun; 21(21-22):3030-42. PubMed ID: 12798647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody.
    Charoenvit Y; Mellouk S; Sedegah M; Toyoshima T; Leef MF; De la Vega P; Beaudoin RL; Aikawa M; Fallarme V; Hoffman SL
    Exp Parasitol; 1995 May; 80(3):419-29. PubMed ID: 7729477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intrasplenic immunization with infected hepatocytes: a mouse model for studying protective immunity against malaria pre-erythrocytic stage.
    Rénia L; Rodrigues MM; Nussenzweig V
    Immunology; 1994 May; 82(1):164-8. PubMed ID: 7913914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen.
    Rogers WO; Weiss WR; Kumar A; Aguiar JC; Tine JA; Gwadz R; Harre JG; Gowda K; Rathore D; Kumar S; Hoffman SL
    Infect Immun; 2002 Aug; 70(8):4329-35. PubMed ID: 12117942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
    Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
    Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium yoelii Infection.
    Leite JA; Bargieri DY; Carvalho BO; Albrecht L; Lopes SC; Kayano AC; Farias AS; Chia WN; Claser C; Malleret B; Russell B; Castiñeiras C; Santos LM; Brocchi M; Wunderlich G; Soares IS; Rodrigues MM; Rénia L; Costa FT
    Infect Immun; 2015 Oct; 83(10):3781-92. PubMed ID: 26169268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunization of mice with live-attenuated late liver stage-arresting Plasmodium yoelii parasites generates protective antibody responses to preerythrocytic stages of malaria.
    Keitany GJ; Sack B; Smithers H; Chen L; Jang IK; Sebastian L; Gupta M; Sather DN; Vignali M; Vaughan AM; Kappe SH; Wang R
    Infect Immun; 2014 Dec; 82(12):5143-53. PubMed ID: 25267837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use.
    Hoffman SL; Doolan DL; Sedegah M; Aguiar JC; Wang R; Malik A; Gramzinski RA; Weiss WR; Hobart P; Norman JA; Margalith M; Hedstrom RC
    Vaccine; 1997 Jun; 15(8):842-5. PubMed ID: 9234529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.
    Richie TL; Charoenvit Y; Wang R; Epstein JE; Hedstrom RC; Kumar S; Luke TC; Freilich DA; Aguiar JC; Sacci JB; Sedegah M; Nosek RA; De La Vega P; Berzins MP; Majam VF; Abot EN; Ganeshan H; Richie NO; Banania JG; Baraceros MF; Geter TG; Mere R; Bebris L; Limbach K; Hickey BW; Lanar DE; Ng J; Shi M; Hobart PM; Norman JA; Soisson LA; Hollingdale MR; Rogers WO; Doolan DL; Hoffman SL
    Hum Vaccin Immunother; 2012 Nov; 8(11):1564-84. PubMed ID: 23151451
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines.
    Brice GT; Dobaño C; Sedegah M; Stefaniak M; Graber NL; Campo JJ; Carucci DJ; Doolan DL
    Microbes Infect; 2007 Oct; 9(12-13):1439-46. PubMed ID: 17913540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
    Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
    Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
    Alaro JR; Lynch MM; Burns JM
    Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.